EE524 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in Costa Rica
Abstract
Authors
A.M. Rendon R. Cordoba V. Wurcel R. Rubino M. Junqueira A. Haiderali M. Huang A. Khandelwal S. Gotarkar